A5051272739- Retinopathy of Prematurity Studies
- Retinal Diseases and Treatments
- Neonatal Health and Biochemistry
- Neonatal Respiratory Health Research
- Ophthalmology and Eye Disorders
- Cytomegalovirus and herpesvirus research
- Ocular Diseases and Behçet’s Syndrome
- Glaucoma and retinal disorders
- Neonatal and fetal brain pathology
- Neonatal and Maternal Infections
- Intraocular Surgery and Lenses
- Vascular Malformations and Hemangiomas
- Cancer Genomics and Diagnostics
- Genetic Syndromes and Imprinting
- Herpesvirus Infections and Treatments
- Vascular Tumors and Angiosarcomas
- Gestational Diabetes Research and Management
- Ophthalmology and Visual Impairment Studies
- Epigenetics and DNA Methylation
- Cardiovascular Conditions and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Gastric Cancer Management and Outcomes
- Retinal and Optic Conditions
- Viral Infections and Vectors
- Preterm Birth and Chorioamnionitis
Texas Children's Hospital
2017-2024
University of Delhi
2021-2024
Baylor College of Medicine
2014-2022
Purpose.: To measure serum levels of bevacizumab and to compare free vascular endothelial growth factor (VEGF) insulin-like factor-1 (IGF-1) in infants who were treated with either intravitreal injection (IVB) or laser for type 1 retinopathy prematurity (ROP). Methods.: Twenty-four ROP randomized into three treatment groups: IVB at 0.625 mg per eye dose, 0.25 laser. Blood samples collected prior on posttreatment days 2, 14, 42, 60. Weekly body weights documented from birth until 60 post...
Intravitreous bevacizumab (0.25 to 0.625 mg) is increasingly used treat type 1 retinopathy of prematurity (ROP), but there remain concerns about systemic toxicity. A much lower dose may be effective while reducing risk.To find a intravitreous that was than previously for severe ROP, in this study, and could tested future larger studies.Between May 2015 September 2016, 61 premature infants with ROP or both eyes were enrolled masked, multicenter, phase de-escalation study. One eye 10 14...
Cytomegalovirus (CMV) is the most common congenital viral infection in United States. Visual and ocular sequelae adolescents adults who are congenitally infected with CMV have not been well studied. Better understanding of long-term visual can help early detection, intervention appropriate educational accommodations.This study evaluated 237 patients (77 symptomatic, 109 asymptomatic 51 control) underwent a series age-appropriate ophthalmologic, audiologic neurodevelopmental examinations from...
Intravitreous bevacizumab (0.25 mg to 0.625 mg) is commonly used treat type 1 retinopathy of prematurity (ROP), but there are concerns about systemic toxicity, particularly the risk neurodevelopmental delay. A much lower dose may be effective for ROP while reducing risk. Previously, after testing doses 0.25 0.031 mg, as low were found in small cohorts infants.To find lowest intravitreous severe ROP.Between April 2017 and May 2019, 59 premature infants with or both eyes enrolled a masked,...
<h3>Importance</h3> This is the first large-scale randomized clinical trial evaluating effectiveness and safety of overminus spectacle therapy for treatment intermittent exotropia (IXT). <h3>Objective</h3> To evaluate spectacles to improve distance IXT control. <h3>Design, Setting, Participants</h3> conducted at 56 sites between January 2017 2019 associated with Pediatric Eye Disease Investigator Group enrolled 386 children aged 3 10 years IXT, a mean control score 2 or worse, refractive...
Long-term hearing outcomes among children with symptomatic congenital cytomegalovirus (CMV) disease who received 6-week ganciclovir therapy early in life are unknown.Longitudinal study of 76 CMV disease, born 1983-2005, were categorized into three groups: group A treated ganciclovir; B untreated had microcephaly, chorioretinitis, or sensorineural loss (SNHL; ≥25 dB) diagnosed the first month (congenital); and C did not meet criteria for B.Patients groups (n = 17), 27), 32) followed to median...
Purpose: We compared changes of plasma angiogenesis cytokine profiles in infants who were treated with intravitreal injection bevacizumab (IVB) for type 1 retinopathy prematurity (ROP) age-matched preterm non-ROP infants. Methods: Thirteen ROP and 13 included. Blood samples collected prior to treatment (time 0) 6 weeks after the 42). Plasma levels nine cytokines from growth factor panel seven soluble receptors measured using a magnetic multiplex assay. Results: changed time 0 42 both groups....
Background: To circumvent possible systemic side effects, anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF) for ocular neovascular diseases in adults are approved only intravitreal administration. However, injection itself can elicit injection-related adverse and premature eyes of infants with retinopathy prematurity (ROP) may be particularly susceptible to injection. Therefore, an unmet clinical need is develop safe therapies ROP. We recently reported that...
Purpose: To describe the presentation, evolution, and long-term outcome of cortical visual impairment (CVI) in patients with symptomatic congenital cytomegalovirus (CMV) infection, to identify risk factors for development CVI CMV. Methods: Retrospective subanalysis a prospective cohort study data gathered from 1982 2013. Results: Eleven 77 (14.3%) CMV, 0 109 asymptomatic 51 control had CVI. Overall, CMV worse vision than who turn patients. Microcephaly, intracranial calcification, dilatation...
In this paper we report long-term therapy management based on iterative de novo molecular and cellular analysis in a case of metastatic non-small cell lung cancer (NSCLC), with prior history treated colorectal cancer. the described temporal tumor evolution, emergent resistance disease recurrences were addressed via administration personalized label- organ-agnostic treatments profiling. This adaptive treatment strategy countered progression at each instance led to durable regression primary...